Protea Biosciences Group Inc., a leading developer of technologies and services for biomolecular analysis, announced the opening of a dedicated customer demonstration and training center for its LAESI (laser ablation electrospray ionization) DP-1000 system. The facility, located in the Company’s headquarters in Morgantown, West Virginia, uses state-of-the-art mass spectrometers that interface with Protea’s proprietary LAESI DP-1000 system.
“We are excited to provide potential customers with the opportunity to interact first-hand with our LAESI DP-1000 system,” said Alessandro Baldi, Protea’s Vice President and General Manager. “This dedicated facility will allow interested scientists to train on the LAESI DP-1000 and use the system to analyze their samples, allowing them to gain familiarity with the platform and its many applications. The opening of our demonstration and training center follows the successful launch of our Bioanalytical Services laboratory, a 10,000 square foot facility dedicated to conducting bioanalytical projects for biopharmaceutical companies. These two facilities illustrate our commitment to fulfilling our customers’ needs by supplying both products and services, giving them the ability to determine which Protea solution better enhances their research.”
Highlighting expanded applications of Protea’s LAESI technology, several posters featuring LAESI were presented at the 60th Annual American Society for Mass Spectrometry (ASMS) Conference in May.
“For the first time, we presented applications of in vivo mass spectrometry, profiling metabolites directly from cell cultures or bacteria colonies at ambient pressure, with no sample preparation. When profiling a living entity, this means metabolites can be mapped over time, adding an entirely new and valuable dimension to biological research,” Baldi continued.
The posters presented at ASMS 2012 detailed research done by scientists at Protea, as well as esteemed collaborators from prestigious research institutions such as Ohio University, West Virginia University, and FOM Institute AMOLF in Amsterdam. Each of the independent studies highlighted the advantages provided by LAESI DP-1000 over traditional sample methods for mass spectrometry, including its minimal sample preparation, wide range of sample types, 2D & 3D mapping, and high throughput. In these studies the LAESI DP-1000 direct ionization system was interfaced with multiple mass spectrometry platforms, demonstrating its broad commercial potential to enter laboratories worldwide.
Date: June 12, 2012
Source: Protea Biosciences Group Inc. https://proteabio.com/
Filed Under: Drug Discovery
